Share on LinkedInShare on LinkedIn

ARTICLE · 01 MAY 2019

Federal Circuit Affirms Patent-Ineligibility Of Diagnostic Method Claims

Khurana & Khurana, Advocates and IP Attorneys
Explore more from Khurana & Khurana, Advocates and IP Attorneys

On April 1, 2019, the Court of Appeals for the Federal Circuit (CAFC) issued a decision in Cleveland Clinic Foundation v. True Health Diagnostics LLC

IndiaIntellectual Property

On April 1, 2019, the Court of Appeals for the Federal Circuit (CAFC) issued a decision in Cleveland Clinic Foundation v. True Health Diagnostics LLC affirming a decision by the U.S District Court for the Eastern District of Virginia that held claim 1 of U.S. Patent No. 9,575,065 and claims 1 and 2 of U.S. Patent No. 9,581,597 invalid under 35 U.S.C. §101 for being directed to a natural law without reciting an inventive concept beyond the natural law itself.

The Cleveland Clinic Foundation and Cleveland HeartLab, Inc., (collectively, "Cleveland Clinic") appealed from a decision of the United States District Court for the Eastern District of Virginia, dismissing their complaint for patent infringement against True Health Diagnostics LLC under Rule 12(b)(6) and holding claim 1 of U.S. Patent 9,575,065 (the "'065 patent") and claims 1 and 2 of U.S. Patent 9,581,597 (the "'597 patent") invalid under 35 U.S.C. § 101 as directed to an ineligible natural law.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from